NEW YORK (360Dx) – Theradiag today announced a deal to provide its Lisa Tracker kits for monitoring Biogen's Flixabi (infliximab) biosimilar.

Biogen will now be able to supply Lisa Tracker monitoring kits in the competitive tenders in which it participates in France, where the therapeutic firm has marketed two biosimilar drugs, including Flixabi, an autoimmune disease treatment. Today's deal also allows Biogen to offer Lisa Tracker in other European countries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.